In this brief excerpt from The Macro Show earlier today, Hedgeye CEO Keith McCullough discussed how the Fed will interpret today’s late cycle non-farm payroll numbers and its implications for investors.
***Below is today's summary of our internal analysis of recent key economic and policy developments emanating from economies in the aforementioned regions. We thought the summary might be helpful as you ponder the sustainability of this epic short-squeeze in global reflation assets.***
In China, the latest batch of high-frequency growth data point to near-term economic stabilization. In conjunction with reduced capital outflow pressures, greater transparency and recent CNY strength, it’s safe to say the bearish yuan overhang has been lifted – for now, at least. We expect that negative catalyst to resume here in Q2, however, as the USD should start to rise amid heightened risk aversion per our #Quad4 forecast for the U.S. economy. This is all part of our expected path for Chinese economic growth and the RMB (i.e. “walking down the stairs” vs. the consensus view of an inevitable crash).
In Japan, the sour 1Q Tankan Survey, terrible MAR Manufacturing PMI report and declining stock prices all call attention to the efficacy and limits of BoJ monetary policy. This has shifted the Japanese policy debate to the fiscal arena and it would appear that Abe is readying yet another [ineffective] supplementary budget amid his call for other G7 economies to dive into the expansionary fiscal policy pool with him. The frequency with which DM policymakers are acting to spur growth is increasing as the impact of marginal stimulus wanes and demographic headwinds gather steam.
In India, quiet week in terms of economic releases but sequential downticks in both growth and inflation readings of late have perpetuated expectations of dovish monetary policy out of the RBI, which has been a boon to Indian capital markets and the INR of late. That said, however, we do not view the aforementioned market deltas as sustainable amid another bout of global risk aversion – which is something we anticipate here in Q2.
In South Korea, the preponderance of the latest batch of high-frequency growth and inflation data implies a #Quad1 outcome – as do trends across key metrics. That in conjunction with South Korea’s low score within our proprietary EM Crisis Risk Index affords us scope to remain favorably disposed to South Korean capital markets and the KRW.
In Australia, the latest batch of high-frequency growth data came in mixed, while the political situation has taken a decided turn for the worse – at least in units of investor uncertainty. We don’t have an explicit view on the outlook for Australian capital markets, but we do believe the AUD is grossly overbought in the context of what we continue to view as an unsustainable global reflation rally nearing its eventual end.
In Taiwan, economic growth appears to have stabilized per the MAR Manufacturing PMI report and trends across the preponderance of key high-frequency growth data. That in conjunction with inflation that is now accelerating on a sequential and trending basis would seem to support the TWD – if not on an absolute basis, then certainly on a relative basis to other EMEs – amid the next round of global dollar tightening, which itself should occur here in Q2.
In Indonesia, the latest batch of high-frequency growth and inflation data was generally positive, on the margin, but we strongly caution against chasing those deltas with increased allocations to Indonesian capital markets or via the IDR. Recall that Indonesia scored most poorly within our proprietary EM Crisis Risk Index, which itself underscores our bearish bias on Indonesia over the intermediate-to-long term.
In Thailand, the latest batch of high-frequency growth and inflation data came in decidedly mixed, highlighted by the contrast between decelerating BSI (FEB) and accelerating Export growth (MAR). Per Thailand’s low score in our proprietary EM Crisis Risk Index, we remain favorably disposed to the country with respect to the intermediate-to-long term.
In Brazil, the latest batch of high-frequency growth data is generally confirmatory of two of the four reasons we think Brazilian capital markets and the BRL are currently priced to perfection: 1) growth contracted at a slower rate and 2) inflation inflected from a persistent trend of acceleration. That in conjunction with 3) the removal of the bearish CNY overhang and 4) consensus speculation that a post-Rousseff administration led by Michel Temer or Aecio Neves will implement much-needed fiscal and economic reforms (which may lend scope to BCB to ease) has value investors backing up the truck here. We think such actors are setting themselves up to be largely disappointed over the intermediate-to-long term as the path and pace of reform falls well shy of investor expectations amid a looming bankruptcy cycle in Brazil. Refer to Brazil’s elevated score in our proprietary EM Crisis Risk Index for more details.
In Mexico, growth continues to slow on a trending basis. Much like in Indonesia, we find it imprudent for real money investors to chase the recent solid performance of Mexican capital markets and the MXN – the both of which benefited from what we continue to view as an unsustainable global reflation rally. Like its Latin American neighbor Brazil, Mexico scores poorly on our proprietary EM Crisis Risk Index, which underscores our intermediate-to-long-term bearish bias on the country.
In Russia, both the RUB and Russian capital markets are starting to break down amid what may be the first signs of the resurgence of global dollar tightening here in Q2. Russia screens fairly poorly on our proprietary EM Crisis Risk Index, but not nearly as poorly as its oil-producing counterparts in Latin America (namely: Brazil, Mexico and Colombia). As such, we think those looking to re-short commodity-linked EM countries would do better to avoid Russia – which has a substantial degree more political and economic risks priced into its financial markets than its peers.
In South Africa, the latest batch of high-frequency economic data is confirmatory of what we’ve previously identified as the key cyclical risk to South African capital markets – hawkish monetary policy out of the SARB (which we expect to remain ongoing). While that has been a boon to the ZAR, we don’t view its recent gains as sustainable in the context of a the aforementioned global dollar tightening scenario we’ve identified for Q2. Additionally, South Africa scores particularly poorly on our EM Crisis Risk Index, which underscores our intermediate-to-long-term bearish bias on the country.
In Turkey, the latest batch of high-frequency economic data would seem to suggest Turkish economic growth is has likely inflected from its positive run ending in 4Q15. While that is certainly not a positive catalyst, we don’t have an explicit bias on Turkish capital markets or the TRY other than our expectation that both continue to trade in line with broader EM asset class beta from here.
- Is the EM Relief Rally Nearing Its [Eventual] End? (3/23/16)
- Call Replay & Eye Candy | Is This a Generational Buying Opportunity in Emerging Markets? (3/17/16)
Remember 2H14? That is a good summary of #Quad4’s impact on reflation assets. Don't disrespect what falling nominal GDP expectations (amid heightened recession fears nonetheless) might do to the collective risk appetite of investors. The Fed likely cannot opt for QE4 unless stock market declines force their hand. Moreover, there's a lot of time and space between April 1st and the FOMC's June 15th statement (in which they update their S.E.P. and Dot Plot). The April meeting offers no such [potentially bullish] catalyst.
Best of luck out there risk managing the aforementioned pivot!
Takeaway: Enclosed is our REPLAY of our Best Ideas Short call we hosted on T. Rowe Price called Paddling Upstream.
Link to MATERIALS
We hosted a Best Ideas Short call on shares of T. Rowe Price (TROW) yesterday. While a well managed, disciplined investment manager, the secular shift to ETFs and mostly importantly to Large Cap strategies is too pervasive for the firm to meet the Street's expectations in our view. In addition, this predominately equity mutual fund manager is at the wrong part of the cycle operating at peak margins and peak profits with the growing potential for a long overdue market decline to kick off negative operating leverage. The firm has unappreciated equity leverage in its most important product, its target date fund franchise with its "through" asset allocation. Our key takeaways are:
1.) The shift from active to passive continues to accelerate and 67% of passive inflows are going to Large Cap strategies. TROW has the largest percentage of Large Cap product of any public mutual fund manager and when including SMAs, TROW's Large Cap exposure goes to over 40% of total assets-under-management:
2.) The firm's Target Date franchise is its go to source of growth, however the oldest Baby Boomers turned 65 in 2011 and now three Series of TROW target date products are in redemption. The hump gets worse in the distribution into the 2020 series which is the second biggest pool of TD assets for the manager. Target date is the only source of growth currently in the overall complex.
3.) TROW is once again at peak margins and profitability and after setting a new high water mark in 2014 at over 50% pretax margins, results are set to recede. TROW will also be bumping up against a break point in fees at over $500 billion in mutual fund AUM which won't help margins. We have earnings at $4.06 for 2017, -17% below the Street before considering that the stock's multiple should also contract against the group.
Please let us know of any questions.
Jonathan Casteleyn, CFA, CMT
get free cartoon of the day!
Start receiving Hedgeye's Cartoon of the Day, an exclusive and humourous take on the market and the economy, delivered every morning to your inbox
By joining our email marketing list you agree to receive marketing emails from Hedgeye. You may unsubscribe at any time by clicking the unsubscribe link in one of the emails.
Takeaway: Please note we are removing Restoration Hardware from Investing Ideas (long side) today.
"Since this is a long-term investor product and Retail Sector head Brian McGough doesn’t want to be long it past the summer time (see below), I want to take advantage of this week’s ramp and take it off our long-term list," says Hedgeye CEO Keith McCullough. "Happy to revisit once our macro call plays out."
Here's the bullish case for Restoration Hardware from McGough:
Fundamentally, the name looks outstanding on a TRADE and a TAIL basis. The question lies in TREND.
My point is this…
- The results printed earlier this week were 4Q – they report REALLY late. The next quarter ends in just four weeks.
- If you bought a leather sofa today, you would not take delivery until early May. Therefore that would be 2Q revenue. In other words, RH already knows its 1Q number (which will be reported late May/early June). But people don’t look at it that way.
- RH just issued 1Q guidance that I think leaves room for upside – potentially a lot. Guided to $0.04-$0.06.
Then we get into mid-summer ... when you don’t want to own retail stocks anyway, and there’s 3-6 months before the biz accelerates again. During that time they’ll be spending on infrastructure. Don’t want to own it then.
We like it over the next month ... don’t like it again until Sept/Oct ... and we are WELL above the Street next year.
Hedgeye and the Potomac Research Group are proud to present our first annual Spring Health Policy Conference. This special, invite-only event will be held at The Benjamin Hotel in New York City on Monday, April 4th, 2016 from 9:30am - 4:00pm.
Our lineup of health policy experts will offer an insider's view on their policy outlook and how as practitioners policy is influencing their decision making process.
This exclusive event will be moderated by Hedgeye Healthcare sector head Tom Tobin and feature in-depth presentations and panel discussions. There will be ample opportunity for interaction throughout the day.
SPEAKERS AND TOPICS
CHIP KAHN - Hospital Industry Outlook
Chip Kahn, President and CEO of the Federation of American Hospitals, will shape the regulatory environment for hospitals heading into the Presidential election. Mr. Kahn’s extensive health policy expertise and lengthy Capitol Hill experience make him one of Washington, D.C.’s most effect and accomplished trade association executives.
NEIL HOWE - Demographic Outlook & Healthcare Reform
A historian, economist, and demographer, Neil is also a recognized authority on global aging, long-term fiscal policy and migration. He is a senior associate to the Center for Strategic and International Studies (CSIS) in Washington, D.C., where he helps direct the CSIS Global Aging Initiative.
ANDREW MCKECHNIE - Health Reform Under Republican Administration
Andrew McKechnie, former policy advisor to the Senate Finance Committee, will discuss Republican efforts to repeal the Affordable Care Act and what the law may look like under a Republican controlled White House. Mr. McKechnie was a key negotiator in bipartisan efforts to pass health reform in 2009, with an area of expertise in Republican politics and strategy.
YVETTE FONTENOT - Health Reform Under Democratic Administration
Yvette Fontenot is a partner at Avenue Solutions, a democratic government affairs firm that offers strategicadvice, policy development, and counsel in federal legislative and executive areas. She previously held theposition of Deputy Director of the Office of Health reform at the Department of Health and Human Services(HHS) and has helped to draft and implement the Affordable Care Act (ACA).
ROBERT LASZEWSKI - Managing Transition to Value Based Payment Models
Robert Laszewski, president of Health Policy and Strategy Associates (HPSA), will address the issues facing key stakeholders (Hospitals, MCOs, Physicians and Pharma) as we the transition to value based payment models focused on delivering better quality at a lower cost. HPSA is a policy and marketplace consulting firm specializing in assisting its clients through the significant health policy and market change afoot.
DR. BABER GHAURI - Policy in Practice
Dr. Ghauri, Interim East Division CMIO for Trinity Health, will discuss how policy influences the decision making process of the second largest nonprofit health system in the nation. Dr. Ghauri’s has a deep background in medical informatics and will also discuss how Trinity is using technology to pursue quality and value initiatives.
DR. RICHARD IORIO - Bundled Payments (CCJR)
Richard Iorio, MD, is the William and Susan Jaffe Professor of Orthopaedic Surgery at New York University Langone Medical Center Hospital for Joint Diseases and Chief of Adult Reconstruction at NYU Langone HJD. Dr. Iorio was involved in the Medicare pilot program that led to expansion of the of bundled payment initiative for total knee replacements.
The total percentage of successful long and short trading signals since the inception of Real-Time Alerts in August of 2008.
LONG SIGNALS 80.52%
SHORT SIGNALS 78.68%